TABLE 2

Commercially available blockers for purinergic enzymes and transporters

Molecular TargetInhibitors
CD39Sodium polyoxotungstate (POM-1), 1-amino-4-(4-chlorophenyl)aminoanthraquinone-2-sulfonic acid sodium salt (PSB-069)
CD73Adenosine 5′-(α,β-methylene)diphosphate, N6-benzyl-α,β-methyleneadenosine 5′-diphosphate disodium salt (PSB-12379), 1-amino-4-(anthracen-2-ylamino)-9,10-dioxoanthracene-2-sulfonate (PSB-0963), N6-phenylethyl- adenosine-5′-O-[(phosphonomethyl)phosphonic acid] (PSB-12425),(((S)-(((2R,3S,4R,5R)-5-(6-(benzyloxy)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid (PSB-12431), (((S)-(((2R,3S,4R,5R)-5-(6-(benzylthio)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid (PSB-12553), quercetin
CD38Carba-β-NAD, pseudocarba-β-NAD, luteolin, luteolinidin, kuromanin, 4,4′-dihydroxy-azobenzene (DHAB), ara-F-NAD, ara-NAD, deoxy NR, deoxy-MNR, ara-F-NMN
Nucleoside transporters2,2′,2″,2‴-[[4,8-bis(hexahydro-1(2H)-azocinyl)pyrimido[5,4-d]pyrimidine-2,6-diyl]dinitrilo]tetrakisethanol (8MDP), cilostazol, dilazep, dipyridamole, 5-iodotubercidin, 6-S-[(4-nitrophenyl)methyl]-6-thioinosine (NBMPR), TC-T6000
Adenosine deaminaseerythro-9-(2-Hydroxy-3-nonyl)adenine hydrochloride (EHNA), pentostatin, 1-deazaadenosine, cladribine
  • β-NAD, β-nicotinamide adenine di nucleotide; NBMPR, 6-S-[(4-nitrophenyl)methyl]-6-thioinosine; PSB-069, 1-amino-4-(4-chlorophenyl)aminoanthraquinone-2-sulfonic acid sodium salt; PSB-12431, (((S)-(((2R,3S,4R,5R)-5-(6-(benzyloxy)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; PSB-12553, (((S)-(((2R,3S,4R,5R)-5-(6-(benzylthio)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; TC-T6000, 2,2′-[[4,8-bis[bis(2-methylpropyl)amino]pyrimido[5,4-d]pyrimidine-2,6-diyl]diimino]bis-ethanol.